Newsletter | March 17, 2020

03.17.20 -- Why Complex Disease Needs Gene Therapy

 

Greetings Cell & Gene Readers,

 

While gene therapy is poised to revolutionize the treatment of rare monogenic diseases, the need to treat chronic and complex diseases looms large on the horizon. Read on to learn why complex disease needs gene therapy.

 

Recently, I was a guest on Life Science Connect’s podcast, and I talked about Cell & Gene’s Editorial Advisory Board and why their counsel helps to provide Cell & Gene’s readers original, actionable information. Give it a listen.

 

Erin Harris, editor in chief
Follow me on Twitter

Industry Insights
Moving Forward With Immunotherapies For Cancer
Article | By Barbara Gilmore, Frost & Sullivan

Industry experts joined a panel at Frost & Sullivan's Virtual Think Tank recently to discuss the current state of immunotherapies, implications of research and development occurring today, key challenges, and future approaches to the targeted use of the immune system in cancer treatment. Read their thoughts on immunotherapies and the critical role for the immune system to play, especially in the advanced stages of cancer, since traditional standard-of-care therapies do often work fairly well.

Pharma Production Tech Transfers: Reaping Rewards, Reducing Risks
White Paper | By Thomas Dax, Mirko Gabriele, and Paul Jorjorian, Thermo Fisher Scientific

Transferring production — and the technologies that undergird it — can be risky. The same product can behave differently in different equipment, resulting in low yields or even batch rejections.

Single-Use Systems For Aseptic Fill/Finish
White Paper | By Robert Roy and Jason Collins, IPS-Integrated Project Services

Today’s disposable systems offer improved manufacturing efficiency and better QA and regulatory compliance — and they can be the fastest route to media fills.

Moving Toward A Closed CAR-T Cell Manufacturing Process
Poster | By Devina Ramsaroop, Steven Loo Yong Kee, Danylo Sirskyj, Calley Hirsch, Elizabeth Csaszar, and Aaron Dulgar Tulloch, GE Healthcare Life Sciences

Challenges to overcome in the CAR T manufacturing process include lengthy production times (11 to  21 days), product variability associated with open handling steps, and high manufacturing costs. Here we examine and evaluate individual CAR-T cell unit operations, commercial reagents, and equipment with process closure potential to develop an improved workflow and increased product consistency.

Single-Use Systems For Storing And Shipping Frozen Drug Materials
Article | CPC

The logistics of decoupling drug substance manufacturing from final drug product formulation is now possible using integrated single-use freeze-thaw assemblies that incorporate reliable components.

Data Integrity And The Manufacturing Control Strategy For Life Sciences Manufacturers
Webinar | Werum IT Solutions America, Inc.

As the “manufacturing control strategy” initiative is relatively new, this webinar reveals the new opportunities that arise from the implementation of a manufacturing control strategy and its best practice-based methodologies. The speaker discusses best practice case studies, as well as the enablers, elements, and challenges of the production control strategy implementation.

Solutions
AES “WOLF”: Walk-On Light Fixture For Cleanrooms
AES Clean Technology, Inc.
Connect With Cell & Gene:
      Twitter